May. 20 at 12:35 AM
$MGRX Overall Interpretation
Positives
* Net loss improved vs prior year
* Operating expenses declined
* Multiple commercialization angles (telehealth, TRT, patents, skincare)
* Nasdaq listing remains intact
Concerns
* Extremely low cash balance
* Ongoing dilution risk
* Very small revenue base
* Heavy stock-based compensation
* Dependence on future financing
* Complex related-party/governance structure